Recently, the chimeric antigen receptor T (CAR-T) cell therapy has brought a new breakthrough to the treatment of hematological cancers, especially for therapy-resistant and refractory AML patients, with advantages of specific major histocompatibility complex (MHC)-independent antigen recognition, higher proliferation, and manageable cytotoxic capacity (45). The gene discussed is HLA-C; the disease is acute myeloid leukemia.